Press Releases
Hybrigenics gets approval and funding for a Phase II clinical trial of inecalcitol in psoriasis
Hybrigenics, a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments of proliferative diseases, announces today that AFSSAPS, the French drug agency, has granted authorization for a Phase II clinical...
Press Releases
Launch of Cytocell Aquarius® FISH probe for Leukemia Patient Prognosis Cytocell Ltd
Cytocell announced today the launch of its latest FISH probe to aid in determining the prognosis of patients with chronic lymphocytic leukemia (CLL), a cancer of the lymphocytes. Cytocell’s Aquarius® P53/ATM Probe Combination detects cytogenetic abnormalities in bone marrow...
Press Releases
Telemedicine Technology Links Rural Arizona to Concussion Care at Mayo Clinic
A pilot program at Mayo Clinic using telemedicine technology is showing promise for patients with concussions in rural Arizona. Doctors at Mayo Clinic in Phoenix recently conducted a live audio-video evaluation of a 15-year-old soccer player in Show...
Press Releases
STERIS invests in the future of sterilization monitoring STERIS
STERIS, a global leader in decontamination and infection control, has recently announced major new investment in its Albert Browne Ltd subsidiary, helping to ensure the future development of this world class and globally trusted brand of sterilisation monitoring...
Press Releases
Mannatech Enhances Omega-3 Supplement with Vitamin D Mannatech Incorporated
Mannatech, Incorporated, the leading innovator and provider of nutritional supplements and skin care products based on Real Food Technology® solutions, recently announced the reformulation of its omega-3 supplement to now include vitamin D. The...
Press Releases
Trophos awarded key US patent covering use of novel cardioprotective compound, TRO40303
Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent...
Press Releases
Hybrigenics maintains stable EUR two million revenues in first half of 2011
Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments of proliferative diseases and specialised in protein interactions, today announces its revenues and cash position for the first...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read